News | January 28, 2024
Novartis India posts Q3 FY24 PAT at Rs. 26.57 Cr
Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023
Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
The company has posted net profit of Rs.33.57 crores for the 9 Months period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
